This information is intended for healthcare professionals based in Belgium and Luxembourg.
If you are not a healthcare professional, click here

Opdivo_Yervoy_Logo Opdivo_Yervoy_Logo Opdivo_Logo Opdivo_Chemotherapy_Logo
Neoadjuvant NSCLC Metastatic NSCLC Mesothelioma
Neoadjuvant NSCLC Metastatic NSCLC Mesothelioma
Renal Cell Carcinoma Urothelial cancer
Renal Cell Carcinoma Urothelial cancer
Advanced MelanomaAdjuvant Melanoma
Adjuvant esophageal (EC or GEJC) 1L adenocarcinoma upper GI 1L or 2L esophageal squamous cell carcinoma (ESCC)
Head & Neck
Hodgkin Lymphoma

Urothelial Cancer

• THE FIRST I-O IN COMBINATION WITH CT IN 1L mUC

Urothelial Cancer

• THE FIRST ADJUVANT IMMUNOTHERAPY IN MIUC

View indication details

  • OPDIVO in combination with cisplatin and gemcitabine is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma
  • OPDIVO as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of MIUC
  • OPDIVO as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy (only reimbursed in Belgium in case of prolongation requests for existing beneficiaries)
Expert opinion

NEW

Recent advances in the treatment
of unresectable and metastatic urothelial cancer

NEW

Pr. Rottey on nivolumab + chemo as 1L therapy for mUC

NEW

Dr. Martinez on latest results of nivolumab in MIUC and updated ESMO guidelines for mUC

CheckMate 901 publication

Product information

NEW

What you need to know
about Opdivo + CT in 1L mUC

What you need to know
about OPDIVO in MIUC

Dosing schemes
in UC

Practical user guide
based on OPDIVO SmPC

PD-L1 testing
overview for OPDIVO

Patient & nurse materials

Patient brochure
with practical information
on immunotherapy

www.immunooncology.be

An educational website
on immunotherapy for your
nurses and your patients

Patient alert card
OPDIVO

Useful links

ImmunoScience Academy
An educational multi-disciplinary platform on immunology and immunotherapy

BSMO immunomanager Comprehensive recommendations
on the diagnostic algorithm and treatment of different types of irAE

Belgian Multidisciplinary Immunotoxicity Board (BITOX) Submit your case/questions
about irAEs

BSP poster
 PD-L1 testing
accross tumor indications

MIUC, muscle invasive urothelial cancer; TC, tumor cell; irAE(s), immune-related adverse event(s)

You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise any concerns or questions in relation to the handling of your personal data by Bristol-Myers Squibb Company.